

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 8 JAN 29 PHAR reloaded with new search and display fields
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13 FEB 26 MEDLINE reloaded with enhancements
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19 MAR 16 CASREACT coverage extended
NEWS 20 MAR 20 MARPAT now updated daily
NEWS 21 MAR 22 LWPI reloaded
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 23 MAR 30 INPADOCDB will replace INPADOC on STN
NEWS 24 APR 02 JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:35:21 ON 27 APR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 18:35:29 ON 27 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2007 HIGHEST RN 933069-51-3

DICTIONARY FILE UPDATES: 26 APR 2007 HIGHEST RN 933069-51-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e benecosanol/cn

E1	1	BENECOAT BMI 40L/CN
E2	1	BENECORT BMI 60/CN
E3	0 -->	BENECOSANOL/CN
E4	1	BENEDORM/CN
E5	1	BENEDYNE/CN
E6	1	BENEFAT/CN
E7	1	BENEFAT D/CN
E8	1	BENEFEX/CN
E9	1	BENEFIBER/CN
E10	1	BENEFIBER RESOURCE ORANGE JUICE DRINK/CN
E11	1	BENEFIBRE/CN
E12	1	BENEFIN/CN

=> file merck

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.45

0.66

FILE 'MRCK' ENTERED AT 18:35:52 ON 27 APR 2007

COPYRIGHT (C) 2007 Merck & Co., Inc., Whitehouse Station, New Jersey, USA. All Rights Reserve

FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: OCTOBER 2005

THE MERCK INDEX ONLINE is a service mark of Merck & Co., Inc., Whitehouse Station, NJ, USA and is registered in the United States Patent and Trademark Office.

=> e benecosanol

E1	2	BENECEL/BI
E2	1	BENECKE/BI
E3	0 -->	BENECOSANOL/BI
E4	9	BENEDETTI/BI
E5	9	BENEDICT/BI
E6	1	BENEDICTUS/BI
E7	2	BENEDIKT/BI
E8	1	BENEDORM/BI
E9	1	BENEFEX/BI
E10	5	BENEFICIAL/BI
E11	1	BENEFIEL/BI
E12	1	BENEFIN/BI

=> s benecosanol

L1 0 BENECOSANOL

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.32

0.98

FILE 'MEDLINE' ENTERED AT 18:36:28 ON 27 APR 2007

FILE LAST UPDATED: 27 Apr 2007 (20070427/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s benecosanol

L2 0 BENECOSANOL

=> s policosanol

L3 120 POLICOSANOL

=> s rice bran wax

13543 RICE

2535 BRAN

5238 WAX

L4 1 RICE BRAN WAX
(RICE(W)BRAN(W)WAX)

=> d

L4 ANSWER 1 OF 1 MEDLINE on STN

Full Text

AN 2006657278 IN-PROCESS

DN PubMed ID: 17090480

TI Amended final report on the safety assessment of Oryza Sativa (rice) Bran Oil, Oryza Sativa (rice) Germ Oil, Rice Bran Acid, Oryza Sativa (rice) Bran Wax, Hydrogenated Rice Bran Wax, Oryza Sativa (rice) Bran Extract, Oryza Sativa (rice) Extract, Oryza Sativa (rice) Germ Powder, Oryza Sativa (rice) Starch, Oryza Sativa (rice) Bran, Hydrolyzed Rice Bran Extract, Hydrolyzed Rice Bran Protein, Hydrolyzed Rice Extract, and Hydrolyzed Rice Protein.

AU Anonymous

SO International journal of toxicology, (2006) Vol. 25 Suppl 2, pp. 91-120.
Journal code: 9708436. ISSN: 1091-5818.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals

ED Entered STN: 9 Nov 2006

Last Updated on STN: 11 Apr 2007

=> file ca

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.95

1.93

FILE 'CA' ENTERED AT 18:37:31 ON 27 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Apr 2007 VOL 146 ISS 19

FILE LAST UPDATED: 26 Apr 2007 (20070426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s benecosanol/ab,bi

0 BENECOSANOL/AB

0 BENECOSANOL/BI

L5 0 BENECOSANOL/AB,BI

=> s rice bran wax/ab,bi

75726 RICE/AB
 14603 BRAN/AB
 65301 WAX/AB
 77 RICE BRAN WAX/AB
 ((RICE(W)BRAN(W)WAX)/AB)
 87600 RICE/BI
 17992 BRAN/BI
 80097 WAX/BI
 125 RICE BRAN WAX/BI
 ((RICE(W)BRAN(W)WAX)/BI)

L6 125 RICE BRAN WAX/AB,BI

=> s policosanol/ab,bi

173 POLICOSANOL/AB

206 POLICOSANOL/BI

L7 206 POLICOSANOL/AB,BI

=> s l6 and l7

L8 3 L6 AND L7

=> d 1-3

L8 ANSWER 1 OF 3 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:353369 CA

TI Policosanol composition and its use in treatment of hypercholesterolemia

IN Lahl, William J.

PA Marcor Development Corporation, USA; Shanghai Freeman International
 Trading Co., Ltd.

SO U.S. Pat. Appl. Publ., 4 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005220868	A1	20051006	US 2004-813017	20040331
PRAI	US 2004-813017		20040331		

L8 ANSWER 2 OF 3 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 134:198116 CA

TI Pharmaceutical composition for reducing serum cholesterol levels
 comprising phytosterol and policosanol

IN Sorkin, Harlan Lee, Jr.

PA USA

SO U.S., 3 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6197832	B1	20010306	US 1999-395524	19990914
	US 2001034338	A1	20011025	US 2001-789150	20010220
PRAI	US 1999-395524	A1	19990914		

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 131:149329 CA

TI Composition for reducing serum cholesterol levels

IN Sorkin, Harlan Lee, Jr.

PA USA

SO PCT Int. Appl., 10 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

PI WO 9940922 A1 19990819 WO 1999-US3003 19990212
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 5952393 A 19990914 US 1998-22807 19980212
CA 2321750 A1 19990819 CA 1999-2321750 19990212
AU 9932902 A 19990830 AU 1999-32902 19990212
AU 754710 B2 20021121
EP 1061927 A1 20001227 EP 1999-932475 19990212
R: CH, DE, ES, GB, LI
JP 2002502879 T 20020129 JP 2000-531174 19990212
PRAI US 1998-22807 A 19980212
WO 1999-US3003 W 19990212
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d an ti so pi kwic 1-3

L8 ANSWER 1 OF 3 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:353369 CA
TI **Policosanol** composition and its use in treatment of hypercholesterolemia
SO U.S. Pat. Appl. Publ., 4 pp.
CODEN: USXXCO
PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 2005220868 A1 20051006 US 2004-813017 20040331
TI **Policosanol** composition and its use in treatment of hypercholesterolemia
AB A compn. is provided contg. at least 90% of policosanols obtained from
rice bran wax, wherein the policosanols contain from about 25 to
about 35% of octacosanol, and its use in providing significant
improvements in.
ST hypocholesterolemic **rice bran wax policosanol** compn octacosanol
IT Drug delivery systems
(capsules; **policosanol** compn. and use in treatment of
hypercholesterolemia)
IT Anticholesteremic agents
Human
Hypercholesterolemia
(**policosanol** compn. and use in treatment of
hypercholesterolemia)
IT Low-density lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**policosanol** compn. and use in treatment of
hypercholesterolemia)
IT Drug delivery systems
(powders; **policosanol** compn. and use in treatment of
hypercholesterolemia)
IT Waxes
(rice bran; **policosanol** compn. and use in treatment of
hypercholesterolemia)
IT Bran
(rice, waxes; **policosanol** compn. and use in treatment of
hypercholesterolemia)
IT Drug delivery systems
(solns.; **policosanol** compn. and use in treatment of
hypercholesterolemia)
IT Drug delivery systems
(tablets; **policosanol** compn. and use in treatment of
hypercholesterolemia)
IT 28346-64-7P, Hexacosanol 28351-05-5P, Triacontanol 52783-45-6P,
Tetracosanol 68580-63-2P, Octacosanol 79554-32-8P, Dotriacontanol
142583-61-7P, **Policosanol**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(**policosanol** compn. and use in treatment of hypercholesterolemia)

IT 57-88-5, Cholesterol, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (total; **policosanol** compn. and use in treatment of hypercholesterolemia)

L8 ANSWER 2 OF 3 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 134:198116 CA

TI Pharmaceutical composition for reducing serum cholesterol levels comprising phytosterol and **policosanol**

SO U.S., 3 pp.
 CODEN: USXXAM

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6197832	B1	20010306	US 1999-395524	19990914
US 2001034338	A1	20011025	US 2001-789150	20010220

TI Pharmaceutical composition for reducing serum cholesterol levels comprising phytosterol and **policosanol**

AB A compn. and method for reducing serum cholesterol in humans and animals is provided. The method comprises administering phytosterol and **policosanol** which together produce a synergistic effect in lowering serum cholesterol levels. Preferably the administered compn. includes about 3.2:1 parts by wt. of phytosterol and **policosanol**. A tablet contained cholestatin (min. 88% phytosterols) 250, **rice bran wax** (23-33% **policosanols**) 250, calcium phosphate 261.7, cellulose 49.4, stearic acid 23.8, magnesium stearate 6.8, and silicon dioxide 9.4 mg.

ST pharmaceutical serum cholesterol reducing phytosterol **policosanol**; antihypercholesterolemic tablet cholestatin **rice bran wax**

IT Alcohols, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aliph.; pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

IT Rice (*Oryza sativa*)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (bran, waxes; pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

IT Anticholesteremic agents
 Binders
 Buffers
 Emulsifying agents
 Lubricants
 Preservatives
 (pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

IT Sterols
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phyto-; pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

IT Waxes
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (rice bran; pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

IT Bran
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (rice, waxes; pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

IT Drug delivery systems
 (tablets; pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

IT Fats and Glyceridic oils, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vegetable; pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

IT 57-88-5, Cholesterol, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(lowering of, in blood; pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

IT 37247-92-0, Cholestatin 142583-61-7, **Policosanol**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compn. for reducing serum cholesterol levels comprising phytosterol and **policosanol**)

L8 ANSWER 3 OF 3 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 131:149329 CA

TI Composition for reducing serum cholesterol levels

SO PCT Int. Appl., 10 pp.

CODEN: PIXXD2

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI WO 9940922 A1 19990819 WO 1999-US3003 19990212
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 5952393 A 19990914 US 1998-22807 19980212
CA 2321750 A1 19990819 CA 1999-2321750 19990212
AU 9932902 A 19990830 AU 1999-32902 19990212
AU 754710 B2 20021121
EP 1061927 A1 20001227 EP 1999-932475 19990212
R: CH, DE, ES, GB, LI
JP 2002502879 T 20020129 JP 2000-531174 19990212
AB A compn. for reducing serum cholesterol in humans and animals is provided.
The compn. includes phytosterol and **policosanol** which together produce a
synergistic effect in lowering serum cholesterol levels. Preferably the
compn. includes about 3.2:1 parts by wt. of phytosterol and **policosanol**.
A tablet contained cholestatin (≥88 % phytosterols) 250, **rice**
bran wax (23-33 % **policosanol**) 250, Ca phosphate 261.7, cellulose
49.4, stearic acid 23.8, Mg stearate 6.8, and silica 9.4 mg.
ST anticholesterolemic tablet phytosterol **policosanol**
IT Rice (Oryza sativa)
Rice (Oryza sativa)
Rice (Oryza sativa)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bran, waxes, **policosanol** from; oral formulations contg.
phytosterol and **policosanol** for reducing serum cholesterol
levels)
IT Drug delivery systems
(capsules, soft; oral formulations contg. phytosterol and
policosanol for reducing serum cholesterol levels)
IT Drug delivery systems
(capsules; oral formulations contg. phytosterol and **policosanol**
for reducing serum cholesterol levels)
IT Anticholesteremic agents
(oral formulations contg. phytosterol and **policosanol** for
reducing serum cholesterol levels)
IT Sterols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral formulations contg. phytosterol and **policosanol** for
reducing serum cholesterol levels)
IT Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rice bran, **policosanol** from; oral formulations contg.
phytosterol and **policosanol** for reducing serum cholesterol

levels)

IT Bran
 Bran
 Bran
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (rice, waxes, **policosanol** from; oral formulations contg.
 phytosterol and **policosanol** for reducing serum cholesterol
 levels)

IT Drug delivery systems
 (tablets; oral formulations contg. phytosterol and **policosanol**
 for reducing serum cholesterol levels)

IT Fats and Glyceridic oils, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vegetable, phytosterol from; oral formulations contg. phytosterol and
policosanol for reducing serum cholesterol levels)

IT 57-88-5, Cholest-5-en-3-ol (3 β)-, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (blood; oral formulations contg. phytosterol and **policosanol**
 for reducing serum cholesterol levels)

IT 83-46-5, β -Sitosterol 83-48-7, Stigmasterol 474-62-4, Campesterol
 37247-92-0, Cholestatin
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU
 (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (oral formulations contg. phytosterol and **policosanol** for
 reducing serum cholesterol levels)

IT 142583-61-7, **Policosanol**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oral formulations contg. phytosterol and **policosanol** for
 reducing serum cholesterol levels)

=> log y

COST IN U.S. DOLLARS

SINCE FILE
 ENTRY

TOTAL
 SESSION

FULL ESTIMATED COST

40.17

42.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
 ENTRY

TOTAL
 SESSION

CA SUBSCRIBER PRICE

-2.19

-2.19

STN INTERNATIONAL LOGOFF AT 18:49:10 ON 27 APR 2007